Mites are considered a threat to the commercial poultry industry due to their direct and indirect pathogenic effects. Dermanyssus gallinae is among the mite species that endanger production, as it is hematophagous and poses a serious sanitary risk. Recently, Tyrophagus putrescentiae has also drawn attention as a potential pest in the poultry industry, and its attacks have been related to clinical symptoms such as cutaneous eruptions and bird restlessness.
View Article and Find Full Text PDFMites are among the major sources of domestic and occupational allergens worldwide, and continuous exposure to these allergens leads to chronic airway inflammation. One of the most allergenic species is the storage mite Tyrophagus putrescentiae (Schrank). Protein extracts are produced from this mite for tests that help the clinical diagnosis (via prick test), treatment, and monitoring of disease progression in patients who had positive results for allergic reactions.
View Article and Find Full Text PDFTyrophagus putrescentiae (Schrank) (Acaridae) is one of the most allergenic mite species worldwide, and it particularly infests household environments, animal feed factories, and food factories. It has been the aim of several studies recently in the healthcare area due to its allergenic potential. However, there had been no records of this species attacking laying birds until this report.
View Article and Find Full Text PDFThis study aimed to evaluate the effect of three different concentrations of discontinuous gradients of percoll (90/45, 80/40, and 70/35) in the outcome of porcine in vitro fertilization (IVF) and its influence on further embryo development and quality. Embryo viability was assessed by the expression of estrogen receptors (E R) and cleaved caspase-3 (CC3). The highest percoll concentration (90/45) resulted in the lowest embryo production (24.
View Article and Find Full Text PDFObjectives: The aim of this study was to evaluate the efficacy, safety, and tolerability of gastrin-releasing peptide (GRP) compared with placebo in autism spectrum disorder symptoms.
Methodology: This is a randomized, double-blind, placebo-controlled crossover trial using GRP 160 pmol/kg for 4 consecutive days in 10 children with autism. Outcomes were measured by the Aberrant Behavior Checklist (ABC) scale.